Life Science Company News

Evercare launches in-home COVID-19 testing, certified for all cross-border travel

HONG KONG, Oct. 21, 2020 /PRNewswire/ -- As Hong Kong prepares for a "health code" and "travel bubble" to open up travel with mainland China, Macau, and Singapore, local start-up Evercare is proactively rolling out an internationally-accepted, 99.9% accurate [1] COVID-19 test designed specifically for cross-border travel. By adopting the WHO-recommended nasal and throat swab testing method, Evercare has tested over 20,000 people, providing official documentation for travel and a unique testing experience at the convenience of their home.

WHO-recommended nasal and throat swab sampling for individuals and corporates

Partnering with one of the largest government-accredited medical laboratories, Evercare's COVID-19 test is generated from the PCR (polymerase chain reaction) methodology, the same approach used by public and private hospitals in Hong Kong. Unlike other service providers, Evercare adopts the internationally-accepted nasal and throat swab testing method instead of the do-it-yourself deep throat saliva test approach. According to research from The Chinese University, saliva tests had a shocking 31% false negative rate, and the rate is two to three times higher if there is no phlegm in the sample. Collecting the nasal and throat sample is easy and pain-free. A registered nurse will use a plastic swab to take a sample from the throat and 1.5 to 2 cm into the nostril, which is far less invasive than the 4cm required for nasopharyngeal swabs. Results will be ready within 24 to 48 hours of testing, and can be ready on the same day with express service.

For corporate partners, Evercare helps companies test their employees before they return to the office. Regular tests for workers can prevent the virus' spread and boost employees' confidence about coming back to work. Under this scheme, registered nurses visit the workplace to administer testing, reducing employees' travel time and raising work productivity.

"The health of our community has always been our number one priority. When COVID-19 began to spread, we realised it was our responsibility to contribute", said Kenneth Wong, CEO of Evercare. "We chose the nasal and throat swab testing method as it is internationally-accepted and suitable for all cross-border travel. With the rising tide of COVID infections re-emerging across Europe, the U.S., and rest of the world, Evercare opts for safety and accuracy over speed. Our health is our most important asset, and we hope to play our part in fighting the pandemic, together."

[1] Evercare is partnered with one of the testing institutions recognised by the Hong Kong SAR Government.

About Evercare

Evercare's mission is to help our parents and grandparents live safely at home. We offer professional home care services for the elderly, specialising in cancer, stroke, dementia and rehabilitative care.

Founded in 2016, Evercare has delivered more than 100,000 hours of professional home care, empowering our loved ones to live with dignity and independence.

In light of the COVID-19 pandemic, Evercare launched Hong Kong's first in-home COVID-19 testing, certified for all cross-border travel. The test is administered only by nurses with 99.9% accuracy and guarantees a 24-hour turnaround time in the safety and comfort of your home.

Evercare's awards range from being a 'Finalist for the Best Home Care Operator' in the Asia Pacific Eldercare Innovation Awards 2018, to being accepted into the Cyberport Incubation Programme 2020, while being selected by the Social Welfare Department as a Recognised Service Provider of the 'Community Care Service Voucher for the Elderly' (CCSV). Our team of advisors include the President of the Hong Kong Alzheimer's Disease Association and doctors in specialties such as orthopaedics and neurosurgery to provide holistic care for your loved ones at home.

Website: https://covid19-test.yourevercare.com/en

SOURCE Evercare

- 21 Oct 2020
Back to overview

Enhance your business development with Biotechgate